Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Aromatase inhibitor Stories

2011-03-01 07:30:00

WALTHAM, Mass., March 1, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response. The trial, to be conducted under a...

2011-02-02 13:13:59

Researchers say breast cancer therapy contributes to early-in-life hip fractures A hip fracture is not common in a 54-year-old woman, unless she is a 54-year-old breast cancer survivor, according to a new Northwestern Medicine study. Researchers found that a combination of early menopause due to breast cancer treatment and common drugs used to treat breast cancer, could be weakening the bones of breast cancer survivors once they hit middle age, leading to hip fractures. Results of the study...

2011-01-24 15:26:08

A new study has found that tamoxifen, an anti-estrogen breast cancer medication, may reduce an individual's risk of death from lung cancer. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study supports the hypothesis that there is a hormonal influence on lung cancer and that estrogen levels play a role in lung cancer patients' prognosis. Previous research suggests that menopausal hormone therapy increases women's risk of dying from lung cancer....

2011-01-24 08:49:27

(Ivanhoe Newswire) -- The anti-estrogen breast cancer drug tamoxifen may reduce the risk of death from lung cancer. A new study suggests that there is a hormonal influence on lung cancer and that estrogen levels play a role in lung cancer patients' prognosis. Elisabetta Rapiti, M.D., of the Geneva Cancer Registry, led a study that compared lung cancer incidence and mortality among breast cancer patients who were and weren't treated with tamoxifen. The study included 6,655 women who were...

2010-12-14 00:01:39

Results from an ongoing study examining two drugs to prevent breast cancer found that the drug raloxifene (Evista) was as almost effective as the standard drug tamoxifen (Nolvadex) and also produced fewer side effects. Earlier results of the study had shown that raloxifene was as effective as tamoxifen in reducing non-invasive breast cancer in post-menopausal women at high risk of developing the disease. For both drugs, women experienced a 50 percent reduction in breast cancer risk after 4...

2010-12-13 08:00:16

A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone sensitive early-stage breast cancer. Dawn L. Hershman, M.D., M.S., associate professor of medicine and epidemiology and co-director of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at Columbia University, presented detailed study results at the 33rd...

2010-12-13 07:49:02

Use of aromatase inhibitors in early stage breast cancer patients affected; older women more likely to discontinue early because of high co-payments A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone sensitive early stage breast cancer. Dawn L. Hershman, MD, associate professor of medicine and epidemiology and co-director of the...

2010-11-08 19:04:57

Breast cancer patients are more likely to have joint pain from taking aromatase inhibitors (AIs) if they have advanced stage cancer, according to a study presented at the American College of Rheumatology's annual meeting, held Nov. 7-11, in Atlanta. The study is one of the first to identify factors that increase the likelihood that a patient will suffer joint pain from AI therapy. AIs, the standard adjuvant therapy for post-menopausal breast cancer, can cause joint pain in patients, mostly in...

2010-11-05 07:00:00

THOUSAND OAKS, Calif., Nov. 5, 2010 /PRNewswire/ -- Amgen (Nasdaq: AMGN) is pleased to announce that it has won the Best New Drug award for Prolia(TM) (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the 2010 Scrip Awards ceremony Nov. 4 in London. Named one of TIME's Top 10 Medical Breakthroughs of 2009, Prolia is the first treatment specifically designed to target osteoclasts, the cells that break...

2010-10-21 00:46:33

Estrogen therapy used by menopausal women causes a type of ovarian cancer to grow five times faster, according to a new study by researchers at the University of Colorado Cancer Center. Menopausal estrogen replacement therapy (ERT) also significantly increases the likelihood of the cancer metastasizing to the lymph nodes, according to the study, which will be published in the Nov. 1 issue of Cancer Research. The study was released online Oct. 19, 2010. Cancer Research, published by the...